Abstract
Purpose
The role of USP11 as a crucial regulator in cancer has gained significant attention due to its deubiquitinating enzyme catalytic activity. However, a comprehensive evaluation of USP11 in pan-cancer studies is currently lacking.
Methods
Our analysis incorporates data from multiple sources, including five immunotherapy cohorts, thirty-three cohorts from The Cancer Genome Atlas (TCGA), and sixteen cohorts from the Gene Expression Omnibus (GEO), two of which were transcriptomic at the single-cell level.
Results
Our findings show that the aberrant expression of USP11was found to be predictive of survival outcomes in various cancer types. And the highest frequency of genomic alterations occurred in uterine corpus endometrial carcinoma (UCEC), and single-cell transcriptome analysis of UCEC further revealed a significantly higher expression of USP11 in plasmacytoid dendritic cells and mast cells. Notably, the expression of USP11 was related to the infiltration levels of CD8+ T cells and natural killing (NK) activated cells. Furthermore, in the skin cutaneous melanoma (SKCM) phs000452 cohort, patients who had higher levels of USP11 mRNA during immunotherapy experienced a significantly shorter median progression-free survival.
Conclusion
Based on our findings, USP11 emerges as a promising molecular biomarker with potential implications for predicting patient prognosis and immunoreaction in pan-cancer.